NRC FORM 591M PART 1
(10-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
The Community Hospital Munster, IN REPORT 2008-001	U.S. Nuclear Regulatory Commission Region III 2443 Warrenville Road Suite 210 Lisle, Illinois 60532-4351

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-09964	13-15882-01	April 1 & 2, 2008

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☒ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Deborah A. Piskura	DA Piskura	4/2/2008

NRC FORM 591M PART 3
(10-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
The Community Hospital REPORT **2008-001**	**Region III** **2443 Warrenville Road, Suite 210** **Lisle, IL 60532**

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
030-09964	13-15882-01	April 1 & 2, 2008

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87130, 87131, & 87132	03.01, 03.02, 03.03, 03.04, 03.05, 03.06, 03.07, and 03.08

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02240	G 2	Eric W. Zickgraf, Ph.D., RSO	219.836.7368

[X] Main Office Inspection — Next Inspection Date: April 2010

[ ] Field

[ ] Temporary Job Site Inspection

PROGRAM SCOPE

This licensee was a community hospital authorized to use materials permitted in Sections 35.100, 35.200, 35.300, 35.400, 35.500, 31.11, I-125 Gliasite radiotherapy system, and iridium-192 in an HDR unit.. The nuclear medicine department was staffed with 8 full-time technologists who performed approximately 750-900 diagnostic nuclear medicine procedures monthly. Nuclear medicine activities were performed in two separate areas within the hospital (diagnostic studies within the nuclear medicine department and nuclear cardiology studies in the cardiac center). The department received bulk Tc-99m and unit doses from a licensed nuclear pharmacy. Typically in a year, the hospital administered I-131 for 50-60 treatments of hyperthyroidism and 50 whole body CA follow up studies. Radioiodine was obtained from a licensed nuclear pharmacy in capsule form. Thyroid carcinoma treatments were administered by the radiation oncology department. The licensee retained the services of a consulting physicist who audited the nuclear medicine radiation safety activities on a quarterly basis.

The radiation therapy department was staffed with 1 authorized medical physicist, 1 dosimetrist, and 3 physicians (authorized users). Cs-137 sources were used in temporary low dose rate implants for typically 1-2 patient treatments per year. The department possessed an HDR unit and administered approximately 150 patient treatments per year; the majority of these treatments were for breast and gynecological cancers. All HDR patient treatments were administered by the attending radiation oncologist and the authorized medical physicist. Source exchange, maintenance, and repairs on the HDR unit were performed by the manufacturer. All I-131 thyroid carcinoma treatments were administered by the radiation therapy department (30 cases each year). The department also used Pd-103 for permanent prostate implants to treat approximately 20-25 cases per year. To date, the licensee administered one I-125 Gliasite treatment .Occasionally, the department administered Sm-153 Quadramet and Y-90 Zevalin dosages; typically 1-2 treatments annually.

This inspection consisted of interviews with licensee personnel, a review of select records, tours of the nuclear medicine and radiation oncology departments, and independent measurements. The inspector observed the administration of several diagnostic nuclear medicine procedures. The inspection included observations of dose calibrator QA checks HDR safety checks, confirmatory inventory of brachytherapy sources, security of byproduct material, use of personnel monitoring, and package receipts and surveys.